Roche Agrees To Acquire Telavant, Including Rights To Novel TL1A-Directed Antibody (RVT-3101), From Roivant Tor $7.1B
Portfolio Pulse from Benzinga Newsdesk
Roche has agreed to acquire Telavant, including rights to the novel TL1A-Directed Antibody (RVT-3101), from Roivant for $7.1 billion. The deal gives Roche the rights to develop, manufacture, and commercialize RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially other diseases. Roche will also have an option to collaborate globally with Pfizer on a next-generation p40/TL1A directed bispecific antibody, currently in Phase 1. Telavant was jointly formed by Roivant and Pfizer in 2022.
October 23, 2023 | 5:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer could potentially benefit from a global collaboration with Roche on a next-generation p40/TL1A directed bispecific antibody, currently in Phase 1.
The potential global collaboration with Roche on a next-generation p40/TL1A directed bispecific antibody could potentially expand Pfizer's product portfolio and strengthen its position in the market.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Roche's acquisition of Telavant and rights to RVT-3101 could potentially strengthen its portfolio in the treatment of inflammatory bowel disease and other diseases.
The acquisition of Telavant and the rights to RVT-3101 could potentially expand Roche's product portfolio and strengthen its position in the market for the treatment of inflammatory bowel disease and potentially other diseases.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Roivant's sale of Telavant and rights to RVT-3101 to Roche for $7.1 billion could potentially provide a significant cash influx.
The sale of Telavant and the rights to RVT-3101 to Roche for $7.1 billion could potentially provide Roivant with a significant cash influx, which could be used for further investments or to strengthen its financial position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100